B Cell Lymphoma
From the Journals
Number of cancer survivors with functional limitations doubled in 20 years
The 70% prevalence of functional limitation among survivors in 2018 is nearly twice that of the general population.
From the Journals
CLL: Black patients die sooner than White patients
Researchers suspect that multiple factors – including biology – could be behind the racial disparity found in this large study.
Opinion
A 50-year-old White male presented with a 4- to 5-year history of progressively growing violaceous lesions on his left lower extremity
A 50-year-old presented with a 4- to 5-year history of progressively growing violaceous lesions on his left lower extremity, unresponsive to over-...
From the Journals
B-cell cancers: Sparse insight into preventing infections
Doctors treating CLL and other B-cell cancers are blindsided by a lack of research into acquired hypogammaglobulinemia prophylactics.
From the Journals
CLL and surgery are more compatible than ever
As patients fare better with targeted therapy, physicians say they can tolerate more procedures.
From the Journals
Erythema extent predicts death in cutaneous GVHD
Study: Extent of skin erythema correlates with deaths from graft-versus-host disease in blood cancer patients after stem cell transplants.
From the Journals
CLL treatment: More infections among real-world patients
Among real-world blood cancer patients treated with three drugs, study finds higher infection rates than in clinical trials.
News
FDA OKs zanubrutinib for CLL or SLL
Zanubrutinib for treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma has been greenlighted by the FDA.
News
FDA approves first-in-class drug for follicular lymphoma
New treatment for relapsed/refractory follicular lymphoma, newly approved by the FDA, showed effectiveness in research presented at ASH 2022.
From the Journals
CAR T-cell therapy neurotoxicity linked to NfL elevations
Even prior to CAR T-cell therapy, patients developing related neurotoxic complications show elevated markers of neuronal injury.
From the Journals
Phase 3 data: Zanubrutinib bests standard CLL treatment
Results could spur FDA approval as frontline therapy.